Suppr超能文献

外周型和中轴型脊柱关节炎的自发性、药物诱导和无药物缓解。

Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.

机构信息

Rheumatology, Med. Department I, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.

University of California San Francisco (UCSF), 400 Parnassus Ave, Box 0326, San Francisco, CA 94143, USA.

出版信息

Best Pract Res Clin Rheumatol. 2014 Oct;28(5):807-18. doi: 10.1016/j.berh.2014.10.005. Epub 2014 Nov 10.

Abstract

In spondyloarthritis (SpA), spontaneous remission is best described in reactive arthritis, a form of peripheral SpA. Prior SpA observational studies suggested that a significant percentage of patients reached spontaneous remission; however, these patients were followed up under older, broader European Spondyloarthropathy Study Group (ESSG) criteria or were not defined by specific criteria. In general, they were mixed populations of peripheral and axial disease, and the subsets were not differentiated when assessing end points such as remission. There are limited data on the natural history of axial SpA, in part because of the evolution of the criteria with the more recently developed Assessment of SpondyloArthritis International Society (ASAS) criteria, including the designation of non-radiographic axial SpA and peripheral SpA. Clinical trials have been conducted with various remission end points including withdrawal of therapy to determine remission maintenance. The following review addresses the potential for remission in axial and peripheral SpA based on the data from both observational studies and clinical trials.

摘要

在脊柱关节炎(SpA)中,自发缓解最好在反应性关节炎中描述,这是一种外周型 SpA。先前的 SpA 观察性研究表明,很大比例的患者达到了自发缓解;然而,这些患者是根据旧的、更广泛的欧洲脊柱关节炎研究组(ESSG)标准进行随访的,或者没有通过特定标准来定义。一般来说,它们是外周和轴向疾病的混合人群,在评估缓解等终点时,这些亚组没有得到区分。关于轴向 SpA 的自然病史数据有限,部分原因是随着最近开发的评估脊柱关节炎国际协会(ASAS)标准,标准不断演变,包括非放射性轴向 SpA 和外周 SpA 的指定。已经进行了多项临床试验,采用了各种缓解终点,包括停止治疗以确定缓解的维持。以下综述基于观察性研究和临床试验的数据,讨论了轴向和外周型 SpA 缓解的可能性。

相似文献

4
Can we reduce the dosage of biologics in spondyloarthritis?我们能否减少脊柱关节炎生物制剂的剂量?
Autoimmun Rev. 2013 May;12(7):691-3. doi: 10.1016/j.autrev.2012.08.013. Epub 2012 Aug 23.

引用本文的文献

2
A glance into the future of diagnosis and treatment of spondyloarthritis.强直性脊柱炎诊断与治疗的未来展望
Ther Adv Musculoskelet Dis. 2022 Jul 22;14:1759720X221111611. doi: 10.1177/1759720X221111611. eCollection 2022.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验